{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:07:14Z","timestamp":1785413234963,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcf.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:01:12Z","timestamp":1773205272000},"page":"664-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France"],"prefix":"10.1016","volume":"25","author":[{"given":"Th\u00e9o","family":"Dh\u00f4te","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Grenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Chatron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-9486","authenticated-orcid":false,"given":"Benjamin","family":"Renaud-Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Macey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2881-2740","authenticated-orcid":false,"given":"Marl\u00e8ne","family":"Murris-Espin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-6331","authenticated-orcid":false,"given":"Vincent","family":"Bunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Boussaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Legeai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dorent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"de Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6897-3616","authenticated-orcid":false,"given":"Jennifer","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jcf.2026.03.003_bib0001","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation","volume":"40","author":"Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.003_bib0003","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chest.2022.07.004","article-title":"The changing epidemiology of cystic fibrosis: the implications for adult care","volume":"163","author":"Burgel","year":"2023","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.003_bib0004","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: cystic Fibrosis Foundation consensus guidelines","volume":"18","author":"Ramos","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.003_bib0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1164\/rccm.201303-0429OC","article-title":"Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation","volume":"187","author":"Thabut","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.003_bib0006","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jcf.2021.12.002","article-title":"Outcomes following lung re-transplantation in patients with cystic fibrosis","volume":"21","author":"Chan","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.03.003_bib0007","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jcf.2025.10.007","article-title":"Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Burgel","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"10212","key":"10.1016\/j.jcf.2026.03.003_bib0008","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2026.03.003_bib0009","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01783-2025","article-title":"Advances in cystic fibrosis: CFTR modulator triple combinations","volume":"67","author":"Burgel","year":"2026","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.003_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jcf.2025.12.019","article-title":"Strategies for the identification of people with cystic fibrosis responsive to CFTR modulator triple combinations","volume":"25","author":"Burgel","year":"2026","journal-title":"J Cyst Fibros."},{"issue":"1","key":"10.1016\/j.jcf.2026.03.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01506-2025","article-title":"The European Medicines Agency\u2019s review of Kaftrio (elexacaftor-tezacaftor-ivacaftor): extending its use to all people with CF aged 2 years and older who do not have two class I CFTR variants","volume":"67","author":"Drai","year":"2026","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.003_bib0013","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting Elexacaftor-Tezacaftor-Ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.003_bib0014","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.003_bib0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1164\/rccm.202109-2121LE","article-title":"Major decrease in lung transplantation for patients with cystic fibrosis in France","volume":"205","author":"Martin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.003_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01402-2022","article-title":"Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor-tezacaftor-ivacaftor, Germany, 2012-2021","volume":"61","author":"Ringshausen","year":"2023","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2026.03.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.chpulm.2024.100077","article-title":"A dramatic decline in lung transplantation for Cystic fibrosis in the United States","volume":"2","author":"Milinic","year":"2024","journal-title":"CHEST Pulm"},{"issue":"9","key":"10.1016\/j.jcf.2026.03.003_bib0019","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for Cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.03.003_bib0020","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.jcf.2026.03.003_bib0021","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01959-2023","article-title":"Gathering real-world compassionate data to expand eligibility for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint","volume":"63","author":"Burgel","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.03.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103476","article-title":"Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR class I variants: real-world data from the French compassionate programme","volume":"88","author":"Burgel","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.jcf.2026.03.003_bib0024","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of elexacaftor-Tezacaftor-ivacaftor in adults with cystic fibrosis and advanced lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.003_bib0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"10237","key":"10.1016\/j.jcf.2026.03.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31040-0","article-title":"Organ procurement and transplantation during the COVID-19 pandemic","volume":"395","author":"Loupy","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2026.03.003_bib0027","article-title":"Impact of the Covid-19 pandemic and lung transplantation program in France","volume":"78","author":"Picard","year":"2020","journal-title":"Respir Med Res"},{"key":"10.1016\/j.jcf.2026.03.003_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108171","article-title":"Impact of availability of a highly effective cystic fibrosis treatment (elexacaftor\/tezacaftor\/ivacaftor) on lung transplant waitlist and lung transplantation trends in the US","volume":"245","author":"Merlo","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2026.03.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2024.100171","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States","volume":"7","author":"Pena","year":"2025","journal-title":"JHLT Open"},{"issue":"10","key":"10.1016\/j.jcf.2026.03.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.70317","article-title":"The changing transplant landscape in the era of Elexacaftor\/Tezacaftor\/Ivacaftor: a word of caution","volume":"39","author":"Semenchuk","year":"2025","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.003_bib0032","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.03.003_bib0033","article-title":"2022 Update of indications and contraindications for lung transplantation in France","volume":"83","author":"Le Pavec","year":"2023","journal-title":"Respir Med Res"},{"issue":"2","key":"10.1016\/j.jcf.2026.03.003_bib0034","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S2213-2600(24)00426-0","article-title":"Expanding CFTR modulator access to benefit all patients who are waiting for a lung transplant","volume":"13","author":"Brugha","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jcf.2026.03.003_bib0035","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcf.2025.01.006","article-title":"Racial disparities in lung transplantation for cystic fibrosis in the era of highly effective modulator therapy","volume":"24","author":"Ruck","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2026.03.003_bib0036","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1002\/ppul.27273","article-title":"A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor\/tezacaftor\/ivacaftor","volume":"59","author":"Burdis","year":"2024","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:32:38Z","timestamp":1785411158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1569199326000482"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}